What is a stock summary page? Click here for an overview.
Business Description
Adaptive Biotechnologies Corp
NAICS : 325412
SIC : 2836
ISIN : US00650F1093
Compare
Compare
Traded in other countries / regions
ADPT.USA1HM.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2019-06-27Description
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.49 | |||||
| Equity-to-Asset | 0.38 | |||||
| Debt-to-Equity | 0.44 | |||||
| Debt-to-EBITDA | -0.69 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -1.46 | |||||
| Beneish M-Score | -2.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.4 | |||||
| 3-Year EBITDA Growth Rate | 14 | |||||
| 3-Year EPS without NRI Growth Rate | 11.4 | |||||
| 3-Year FCF Growth Rate | 28.2 | |||||
| 3-Year Book Growth Rate | -31.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 27.23 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 21.91 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.07 | |||||
| 9-Day RSI | 56.47 | |||||
| 14-Day RSI | 53.39 | |||||
| 3-1 Month Momentum % | 5.38 | |||||
| 6-1 Month Momentum % | 89.21 | |||||
| 12-1 Month Momentum % | 222.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.89 | |||||
| Quick Ratio | 2.81 | |||||
| Cash Ratio | 2.27 | |||||
| Days Inventory | 62.13 | |||||
| Days Sales Outstanding | 80.83 | |||||
| Days Payable | 44.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.5 | |||||
| Shareholder Yield % | 0.8 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 59.72 | |||||
| Operating Margin % | -86.81 | |||||
| Net Margin % | -89.12 | |||||
| FCF Margin % | -55.25 | |||||
| ROE % | -63.73 | |||||
| ROA % | -26.9 | |||||
| ROIC % | -48.57 | |||||
| 3-Year ROIIC % | -18.91 | |||||
| ROC (Joel Greenblatt) % | -138.92 | |||||
| ROCE % | -29.37 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.5 | |||||
| PB Ratio | 5.77 | |||||
| Price-to-Tangible-Book | 14.63 | |||||
| EV-to-EBIT | -7.02 | |||||
| EV-to-Forward-EBIT | -1.95 | |||||
| EV-to-EBITDA | -8.07 | |||||
| EV-to-Forward-EBITDA | -2.19 | |||||
| EV-to-Revenue | 5.81 | |||||
| EV-to-Forward-Revenue | 1.5 | |||||
| EV-to-FCF | -10.51 | |||||
| Price-to-GF-Value | 1.16 | |||||
| Earnings Yield (Greenblatt) % | -14.25 | |||||
| FCF Yield % | -8.42 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ADPT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Adaptive Biotechnologies Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 178.957 | ||
| EPS (TTM) ($) | -1.09 | ||
| Beta | 2.05 | ||
| 3-Year Sharpe Ratio | -0.11 | ||
| 3-Year Sortino Ratio | -0.15 | ||
| Volatility % | 55.56 | ||
| 14-Day RSI | 53.39 | ||
| 14-Day ATR ($) | 0.661145 | ||
| 20-Day SMA ($) | 7.61225 | ||
| 12-1 Month Momentum % | 222.61 | ||
| 52-Week Range ($) | 2.555 - 9.01 | ||
| Shares Outstanding (Mil) | 148.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Adaptive Biotechnologies Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Adaptive Biotechnologies Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Adaptive Biotechnologies Corp Frequently Asked Questions
What is Adaptive Biotechnologies Corp(ADPT)'s stock price today?
The current price of ADPT is $7.90. The 52 week high of ADPT is $9.01 and 52 week low is $2.56.
When is next earnings date of Adaptive Biotechnologies Corp(ADPT)?
The next earnings date of Adaptive Biotechnologies Corp(ADPT) is 2025-05-01.
Does Adaptive Biotechnologies Corp(ADPT) pay dividends? If so, how much?
Adaptive Biotechnologies Corp(ADPT) does not pay dividend.
Guru Commentaries on NAS:ADPT
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers